研究表明,长期的抗激疗法有利于患低风险乳腺癌的绝经后期妇女。 Study shows long-term anti-hormonal therapy benefits postmenopausal women with low-risk breast tumors.

最近在《国家癌症研究所期刊》上公布的一项研究表明,患低风险乳腺癌的绝经后妇女至少20年来都从反激素疗法中获得长期好处。 A recent study published in the Journal of the National Cancer Institute reveals that postmenopausal women with low-risk breast tumors see long-term benefits from anti-hormonal therapy for at least 20 years. 然而,尚未经历更年期的年轻妇女却享受短期福利。 However, younger women who have not yet gone through menopause experience shorter-term benefits. 该研究涉及1976年至1997年期间确诊的1 200多名妇女。 这项研究还发现,患有高风险肿瘤的妇女不论更年期状况如何,其受益较少。 The study, involving over 1,200 women diagnosed between 1976 and 1997, also found that women with high-risk tumors had less benefit regardless of menopausal status. 研究人员强调,需要有新的标记来预测年轻病人的长期利益。 Researchers emphasize the need for new markers to predict long-term benefits for younger patients.